Steven Myles Cohen, MD CURRICULUM VITAE

1993-1994 Fellow Bascom Palmer Eye Institute, Miami, FL. Surgical retina fellowship.

Contact: Harry W. Flynn, Jr., M.D.
1992-1993 Fellow Bascom Palmer Eye Institute, Miami, FL. Medical retina fellowship.

Contact: J. Donald M. Gass, M.D.
1989-1992 Resident University of California, Davis, Department of Ophthalmology, Sacramento, CA.
Contact: John L. Keltner, M.D., Chairman.

1988-1989 Intern Transitional Program, The Miriam Hospital, Brown University, Providence, RI.
Contact: Fred Schiffman, M.D., Program Director.

1984-1988 Student Harvard Medical School, Boston, MA. M.D. in Hematology-Oncology, Graduated from the Harvard-M.I.T. Division of Health Sciences and Technology. Graduate thesis Vitamin D and Retinoblastoma.
Contact: Daniel Albert, M.D., Thesis Advisor.

1980-1984 Student Harvard College, Cambridge, MA. B.A. in Applied Mathematics with Honors.
Contact: Carmen Puliafito, M.D., Premedical Advisor.

Florida

May, 2014 American Board of Ophthalmology (re-certification)

May, 2004 American Board of Ophthalmology (re-certification)

May, 1994 American Board of Ophthalmology

Benner JD and Cohen SM; Drug Delivery Company, assignee. Bioresorbable drug eluting intravitreal implant system and method. U.S. Patent No. 9,445,941. September 20, 2016.

Benner JD and Cohen SM; Drug Delivery Company, assignee. Bioresorbable drug eluting intravitreal implant system and method. U.S. Patent No. 9,452,083. September 27, 2016.

Benner JD, Cohen SM, and Lumpkin CF; Drug Delivery Company, assignee. Non-sliding and non-sutured contact lens system for ophthalmic procedures. U.S. Patent No. 9,936,871. April 10, 2018.

Benner JD, Cohen SM, and Lumpkin CF; Drug Delivery Company, assignee. Non-sliding and non-sutured contact lens system for ophthalmic procedures. U.S. Patent No. 10,258,233. April 16, 2019.

Benner JD, Cohen SM, and Lumpkin CF; Drug Delivery Company, assignee. Sub-cutaneous medicinal dosage delivery implant system. U.S. Patent No. 10,307,289. June 4, 2019.

Benner JD, Cohen SM, and Lumpkin CF; Drug Delivery Company, assignee. Non-sliding and non-sutured contact lens system for ophthalmic procedures. U.S. Patent No. 11,039,746. June 22, 2021.

Benner JD, Cohen SM, Vutukuru, NKR et al; Drug Delivery Company, assignee. Extended release bioabsorbable subcutaneous medicinal dosage delivery implant system. U.S. Patent No. 11,197,819. December 14, 2021.

2017-Present www.RetinaUniversity.com – a Moodle based educational website, Retina University was established in March 2017 to provide learning tools for Ophthalmology Residents and Retina Fellows

2010-Present www.RetinaGallery.com – Retina Gallery is a resource for teaching and learning through exchange of interesting retina cases and the sharing of high quality images of retinal diseases.

2010-Present www.MyTBOS.com – A resource for the Tampa Bay Ophthalmological Society member to organize meetings and pay dues and communicate.

2013-23 Elected by his peers for inclusion in Best Doctors in America

2015-23 Castle Connolly Top Doctor

2011 & 2018 David D. Donaldson Clinical Faculty Teaching Award – USF

1987 Lion’s Ophthalmic Research Fellowship

1984 Kirkland House Master’s Award

1981-1984 Harvard Scholarship

1980 Bausch and Lomb Medal for Science Achievement

1979 Westinghouse Science Search High Honors New York State
“A New Model of the Universe”

1994-present Preceptor, Imagina Conference, Tampa General Hospital, Tampa, FL. First Friday of each month, all ophthalmology residents, teaching conference. Present and discuss interesting retinal cases from clinical practice.

2009-2014 Preceptor, Largo Medical Center Residency – Post Graduate Training Program, Largo, Florida.

2003-2014 Preceptor, Longitudinal Clinical Experience, University of South Florida. One half day weekly a first or second year student spends time in my office seeing and discussing patients in my private retina clinic.

1994-2014 Lecturer, Resident morning conference, University of South Florida Department of Ophthalmology morning conference once or twice yearly. One to 2 hour lecture on retina topic for all ophthalmology residents.

1994-1996 Attending, Resident VA Hospital and All Children’s Hospital retina clinic, four times yearly at either VA Hospital in Tampa or All Children’s Hospital. Half day as attending of resident clinic.

Archives of Ophthalmology, American Journal of Ophthalmology, Retina, Journal of Vitreoretinal Surgery.

2008-present Gass Fellowship Society

1996-present American Society of Retinal Specialists

1990-present Fellow of the American Academy of Ophthalmology

1986-present American Medical Association

1999-present American Association for the Advancement of Science

2010 President – Tampa Bay Ophthalmic Society

1996-2009 Aspen Retinal Detachment Society

1994-present Tampa Bay Ophthalmic Society

1994-present Florida Medical Society

1994-2006 Pinellas County Medical Society

1996-2005 American Diabetes Association

1995-2005 Nantucket Retina Society

1989-2003 Association for Research in Vision and Ophthalmology

1989-1992 Contact Lens Association of Ophthalmologists

1989-1992 California Association of Ophthalmology

1989-1992 Alta, Northern California Ophthalmic Society

1989-1991 California Medical Association

1986-1990 Massachusetts Medical Society

Northside Hospital, Bardmoor Surgery Center, Safety Harbor Surgery Center

1992-1994 Study of the Ocular Complications of AIDS (SOCA)

1992-1994 Collaborative Ocular Melanoma Study (COMS)

2005-2007 Diabetic Retinopathy Clinical Research Network (DRCRnet)

2017-Present Chronic Toxoplasma Gondii, Pregnancy Reactivation, and Perinatal Depression, Consultant

2019-present A long-acting bioabsorbable naltrexone subcutaneous implant for opioid use disorder, Co-Prinicpal Investigator

The University of Virginia TOGA-01: Treatment with Oracea for Geographic Atrophy: Phase 2/3 Study Evaluating the Safety and Efficacy of daily oral administration of doxycycline (ORACEA) vs placebo in subjects with GA, Site Sub-PI, 2014-Present.

Ophthotech Protocol OPH1004A SOLARIS: A Phase 3 Randomized,Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista (Anti PDGF-B Pegylated Aptamer) Administered in Combination with Either Avastin or Eylea Monotherapy in Subjects with Neovascular Age-Related MacularDegeneration, Site Sub-PI, 2014-2017.

Thrombogenics Protocol TG-MV-018 ORBIT: Ocriplasmin Research to Better Inform Treatment A Phase 4 Trial Evaluating the Clinical Outcomes and Safety in Patients Receiving Jetrea for the Treatment of Symptomatic Vitreomacular Adhesion, Site Sub-PI, 2014-2016.

Thrombogenics Protocol TG-MV-022 OZONE: A Retrospective Review of Patients Treated with Ocriplasmin for Symptomatic VMA Retrospective Observational Trial, Site Sub-PI, 2015-2016.

Genentech/Roche Protocol GX29185 SPECTRI: A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, Site Sub-PI, 2015-2018.

River Vision DME 01RV Phase 1, Open-Label Safety and Pharmacodynamic Study of RV001, an Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist, Administered by Intravenous Infusion in Patients with Diabetic Macular Edema, 2015-2016.

Allergan Protocol 190342-038 BEACON: A Phase 2 Study Assessing the Safety and Efficacy of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-Related Macular Degeneration, Site Sub-PI, 2015-2018.

Allergan Protocol 150998-005 CEDAR: A Phase 3 Study Assessing the Safety and Efficacy of Abicipar Pegol in Patients with Age-Related Macular Degeneration, Site Sub-PI, 2015-2019.

Alcon Protocol RTH-258-C001 HAWK: A Double-Masked, Multicenter, Three-Arm Phase 3 Study Comparing the Efficacy of RTH-258 Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration, Site Sub-PI 2015-2019.

Genentech/Roche Protocol GX29176 CHROMA: A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, Site Sub-PI, 2016-2018.

Alimera Protocol M-01-15-004 PALADIN: A Phase 4 Safety Study of IOP Signals in Patients Treated with ILUVEIN (Fluocinolone Acetonide Intravitreal Implant), Site Sub-PI, 2016-2018.

Genentech/Roche Protocol BP29647 AVENUE: A Proof-of-Concept Study of RG7716 in Participants with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration, Site Sub-PI, 2015-2017.
Genentech/Roche Protocol BP30099 BOULEVARD: A Phase 2 Study of RO6867461 in Participants with Center-Involving Diabetic Macular Edema, Site Sub-PI, 2016-2018.

Allergan Protocol 150998-006 SEQUOIA: A Phase 3 Study Assessing the Safety and Efficacy of Abicipar Pegol in Patients with Age-Related Macular Degeneration, Site Sub-Investigator, 2016-2019.

Genentech Protocol GX28228 LADDER: A Phase 2 Study of the Efficacy and Safety of the Ranibizumab Prt Delivery System for Sustained Delivery of Ranibizumab in Patient with Subfoveal Age-Related Macular Degeneration, Site Sub-PI, 2016-2019.

Genentech Protocol GX30191 OMASPECT: Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants with Geographic Atrophy Secondary to Age-Related Macular Degeneration, Site Sub-PI, 2016-2018.

Genentech/Roche Protocol CR39521 STAIRWAY: A Phase 2 Study of Simultaneous Blockade of Angiopoietin-2 and VEGF-A with the Bispecfic Antibody RO6867461(RG7716) for Extended Durability in the Treatment of Neovascular Age-Related Macular Degeneration, Site Sub-PI, 2016-2019.

Clearside CLS1003-301 SAPPHIRE: A Phase 2 Study of Suprachoroidal Injection of Triamcinolone Acetonide with IVT Aflibercept in Subjects with Macular Edema Following RVO, Site Co-Sub-PI, 2017-2019.
Opthea OPT-302-1002 OPTHEA: A Dose-Ranging Study of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab alone, in Participants with Neovascular Age-Related Macular Degeneration, Site Sub-PI 2017-2019.

Allergan MAPLE: Evaluation of Abicipar Pegol in Patient with Neovascular Age-related Macular Degeneration. Site Sub-PI 2018-2019.
Genentech GR40549 PORTAL: A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Delivery System with Ranibizumab in Patient with Neovascular Age-Related Macular Degeneration. Site Sub-PI 2018-Present.

Genentech GR40548 ARCHWAY: A Phase III, Multicenter, Randomized, Visual Assessor Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration . Site Sub-PI 2018-2020.

Genentech GR40398 RHINE: A Phase III, Multicenter, Randomized, Double-Masked, Active, Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema. Site Sub-PI 2018-Present.

Chengdu KHB-1801 PANDA: A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration . Site Sub-PI 2018-Present.

Mylan MYL-1701P-3001 INSIGHT: A Multi Center, Randomized, Double-Masked, Active-Controlled, Comparative Clinical Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects with Diabetic Macular Edema. Site Sub-PI 2019-Present.
OPT-302-1003 OPTHEA Study: Phase 1b/2a Study Of OPT-302 in Combination with Aflibercept for Persistent Central-Involved Diabetic Macular Edema. Site Sub-PI 2019-2020.

Genentech GR40306 TENAYA Study: A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration. Site Sub-PI 2019-Present.

Santen 010906IN LUMINA Study: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 μg DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye. Site Sub-PI 2019-Present.

Kodiak KSI-CL-101 Study: A Phase 1/1b Open Label, Multi-Center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age Related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion. Site Sub-PI 2019-Present.

Ionis 696844-CS5 GOLDEN Study: A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration, Site Sub-PI 2019-Present.

Genentech GR40973 GALLEGO Study: A Phase II, Multicenter, Randomized, Single-Masked, Sham−Controlled Study to Assess Safety, Tolerability, and Efficacy of Intravitreal Injections of FHTR2163 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Sub-PI 2019-Present.

Genentech BP40899 DOVETAIL Study: A Multi-Center, Non-Randomized, Open-Label, Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7200220 in Monotherapy and in Combination with Ranibizumab following Intravitreal Administration in Patients with Diabetic Macular Edema. Site Sub-PI 2019-Present.

NGM621 Clinical Study Protocol 18-0501: A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Sub-PI 2019-Present.

Kodiak KSI-CL-102 Study: A Phase 2, Prospective, Randomized, Double-masked, Active Comparator Controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration. Site Sub-PI 2019-Present.

Novartis CRTH258C2305 KINGFISHER Study: A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema. Site Sub-PI 2019-Present.

Novartis CRTH258C2302 RAVEN Study: An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion. Site Sub-PI 2019-Present.

Novartis CRTH258C2301 RAPTOR Study: An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion. SIte Sub-PI 2019-Present.
Gyroscope Therapeutics GTSCOPE Study: A Study of Disease Progression in Genetically Defined Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration. Site Sub-PI 2019-Present.

Genentech GR40550 PAGODA Study: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema. Site Sub-PI 2019-Present.

Carey A and Cohen SM. Paracentral acute middle maculopathy in birdshot chorioretinopathy: a novel association. Retinal Cases and Brief Reports 10:151–153, 2016.

Cohen SM. Co-occurence of acute retinal artery occlusion and acute ischemic stroke: diffusion-weighted magnetic resonance imaging study. Am J Ophthalmol 2014;October 158:850.

Cohen SM, Billiris-Findlay K, Eichenbaum DA, Pautler SE. Topical lidocaine gel with and without subconjunctival lidocaine injection for intravitreal injection: a within-patient study. Ophthalmic Surg Lasers Imaging Retina. 2014 Jul-Aug;45(4):306-10.

Davis A, Cohen SM, Pautler SE et al. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab. Retina 2013;33:2185, Correspondence.

Cohen SM. Dislocated Posterior Chamber Intraocular Lens Management: A new technique using buried-suture and buried-knot transscleral suture fixation without a scleral tunnel or flap. Retina Today October 2013: 58-66.

Cohen SM. New insights into the pathoanatomy of diabetic macular edema: Angiographic patterns and optical coherence tomography. Retina 2013;33(4):893.

Cohen SM. Spectral Domain Optical Coherence Tomography Guided Macular Hole Surgery: Internal Limiting Membrane Peeling Based on pre-operative SD-OCT. Retina Today, January 2013.

Cohen SM. Vascular Remodeling in Central Retinal Vein Occlusion following Laser Induced Chorioretinal Anastomosis. Arch Ophthalmol. 2013;131:403-404.

Witmer M, Cohen SM. Oral Anticoagulation and the Risk of Vitreous Hemorrhage and Retinal Tears in Eyes with Acute Posterior Vitreous Detachment. Retina. 2013;33:621–626.

Nichols-Kay C, Pavan PR, Small LB, Zhang T, Zamba GK, Cohen SM. Prevalence of Familial Trends in Population with Macular Holes. Retina 2012;32:754–759.

Davis A, Cohen SM, Pautler SE, Billiris-Findlay K, Eichenbaum DA. Beta Blocker Use and Age-Related Macular Degeneration. Acta Ophthalmologica. 2012;90:232-233.

Ascaso FJ, Rojo M, Minguez E, Cohen SM, and Yang SS. Bilateral Idiopathic Multifocal Serous Neurosensory Retinal Detachments Resembling Central Serous Chorioretinopathy: Complete Resolution with Corticosteroids. Retina. 1011;3:616-622.

Cohen SM, Reichel E, Arroyo JG, and Lujan BJ.. Diagnostic and Therapeutic Challenges: Tractional Retinal Detachment and Staphyloma. Retina. 2011;1:184-187.

Cohen SM. Perfluoron and silicone oil for complex retinal detachments. Retinal Physician November/December 2009;51-54,69.

Cohen SM. Multiple evanescent white dot syndrome after vaccination for human papilloma virus and meningococcus. J. Pediatr Ophthalmol Strabismus 2009 Jun 25. doi: 10.3928/01913913-20090616-01. Epub 2009 Jun 25. PMID: 19645392

Cohen SM. Optical coherenence tomography in non-proliferative group 2a idiopathic juxtafoveal retinal telangiectasis. (letter) Retina 2008:28;368-370.

Cohen SM, Cohen ML, El-Jabali, F, Pautler, SE. Optical coherence tomography findings in non-proliferative group 2a idiopathic juxtafoveal retinal telangiectasis. Retina 2007:27;59-66.

Cohen SM, Davis AJ, Cukrowski C. Cystoid macular edema following pars plana vitrectomy for retained lens fragments. J Cataract Refract Surg 2006;32:1521-1526.

Cohen SM, Gardner, F. Bilateral choroidal ischemia in giant cell arteritis. Arch Ophthalmol 2006;124:922.

El-Jabali F, Cohen S. Talc retinopathy. New England Journal of Medicine. 2006;354(12):e11.

Cohen SM. Natural history of asymptomatic clinical retinal detachments (letters x 3). Am J Ophthalmol 2005;140:1167-11172.

Cohen SM. Natural history of asymptomatic clinical retinal detachments. Am J Ophthalmol 2005;139:777-779.

Dislocated IOL Study Group. In-the-bag Intraocular Lens Dislocation. Am J Ophthalmol 2004;137:630-635.

Cohen SM. Intraocular Adjuvants, Macular Hole Surgery, and Endophthalmitis. Vitreous society on line journal, 1997 June;1(1):[10 screens]. Available from: URL:http://www.vitreoussociety.org/journal/origin/cohen/machol17.htm

Cohen SM, Flynn HW, Jr., Miller D. Endophthalmitis caused by Serratia marcescens. Ophthalmic Surgery and Lasers 1997;28:195-200.

Cohen SM. Indocyanine green angiography of a laser induced retinochoroidal anastomosis. Ophthalmic Surgery and Lasers 1997;28:65-66.

Cohen SM, Kokame GT, Gass JDM. Paraproteinemias associated with central serous chorioretinopathy. Retina 1996;16:467-473.

Cohen SM, Grizzard WS. Treatment of subfoveal pigment epithelial detachments with distant extrafoveal choroidal neovascular membranes. Br J Ophthalmol 1996;80:929-30.

Lewis ML, Cohen SM, Smiddy WE, Gass JDM. Bilaterality of macular holes. Graefe’s Arch Clin Exp Ophthalmol 1996;234:241-5.

Cohen SM, Davis JL, Gass JDM. Branch retinal arterial occlusions in multifocal retinitis with optic nerve edema. Archives of Ophthalmology 1995;113:1271-1276.

Cohen SM, Flynn HW, Jr., Palmberg PF, Gass JDM, Grajewski AL, Parrish RK, Jr. Treatment of hypotony maculopathy after trabeculectomy.Ophthalmic Surg Lasers 1995;26:435-441.

Cohen SM, Flynn HW, Murray TG, Smiddy WE, The Endophthalmitis after Vitrectomy Study Group. Endophthalmitis after pars plana vitrectomy. Ophthalmology 1995;102:705-712.

Cohen SM, Shen JH, Smiddy WE. Laser energy and dye fluorescence transmission through blood in vitro. American Journal of Ophthalmology 1995;119:452-457.

Cohen SM, Olin KL, Feuer WJ, Hjelmeland l, Keen CL, Morse LS. Low glutathione reductase and peroxidase activity in age-related macular degeneration. British Journal of Ophthalmology 1994; 78:791-794

Cohen SM, Gass JDM. Bilateral radial chorioretinal folds. International Ophthalmology 1994;18:243-246.

Cohen SM, Gass JDM. Macular hole following severe hypertensive retinopathy. Archives of Ophthalmology 1994;112:878-879.

Cohen SM, Keltner JL. Thrombosis of the lateral transverse sinus with papilledema. Archives of Ophthalmology 1993;111:274-275.

Cohen SM, Benner JD, Landers MB, Morse LS. Intraocular cultures after primary pars plana vitrectomy. American Journal of Ophthalmology 1992;114:697-9.

Cohen SM, Sousa FJ, Kelly NE, Wendel RT, Respiratory arrest and new retinal hemorrhages following retrobulbar anesthesia. American Journal of Ophthalmology 1992;113(2):209-211.

Saulenas AM, Cohen SM, Key L, Winter C, Albert DM. Vitamin D and retinoblastoma, the presence of receptors and inhibition of growth in vitro. Archives of Ophthalmology 1988;106:533-535.

Albert DM, Saulenas AM, Cohen SM. Verhoeff’s query: Is vitamin D effective against retinoblastoma? Archives of Ophthalmology 1988;106:536-540.

Cohen SM, Saulenas AM, Sullivan C, Albert DM. Further studies of the effect of vitamin D on retinoblastoma, inhibition with 1,25-dihydroxy-cholecalciferol. Archives of Ophthalmology 1988;106:541-543.

Cohen SM. The artificial iris. Invited Lecture. Florida Society of Ophthalmology Masters in Ophthalmology, Palm Beach, Fl, July 10, 2021.

Cohen SM. Imaging in Age Related Macular Degeneration. Invited Lecture. Mid-Year Program Ophthalmic Photographers Society. Bacom Palmer Eye Institute, The University of Miami, June 7-8, 2019.

Cohen SM. Auto-immune retinopathy. Retina Case Conference, Naples, May 2019

Cohen SM. Successful co-management of Uveitis for the Rheumatologist. Invited Lecture. Florida Society of Rheumatology, Orlando, FL June 2017.

Karumanchi K, Skyrpai Y, Thomas A, Uwensuyi A, Benner J, Cohen SM, and Gaillard ER. Extended release of bevacizumab through nanoliposomes for treating ocular angiogenesis. ARVO May 2017.

Cohen SM. Infrared Reflectance and Spectral Domain OCT Findings Following Pneumatic Retinopexy. Chicago: Annual Meeting of the American Academy of Ophthalmology, October 2014.

Prabakaran S, Cohen SM. Patients undergoing treatment for wet age-related macular degeneration in one eye rarely present for an unscheduled emergent office visit when they develop wet AMD in their second eye. Orlando, ARVO May 2014.

Cohen SM, Muller LT, Espana EM, Behler SC. An Outbreak of Mycobacterium Abscessus Nodular Scleritis Following Intravitreal Injection. New Orleans, Annual Meeting of the American Academy of Ophthalmology, October 2013.

Eichenbaum D, Cohen S, Pautler S, Billiris-Findlay K. A Prospective Study of Ranibizumab for DME: Monthly injections vs Treat-and-Extend. Toronto: American Society of Retinal Specialists, August 2013.

Malavade SS, Cohen SM. Optimal treatment strategy for Stage 5 Type 2A Idiopathic Macular Telangiectasia with anti-vascular endothelial growth factor (VEGF) agents – When to stop?
Seattle, ARVO May, 2013.

Cohen SM. Macular Hole in Group 2a Juxtafoveal Retinal Telangiectasis. Gass Society Meeting. 2010. Vancouver, August 2010.

Cohen SM. The Risk of Subsequent Retinal Tears in Eyes with Acute Posterior Vitreous Detachment and Vitreous Hemorrhage. Annual Meeting of the American Society of Retinal Specialists, Vancouver, August 2010.

Kay CN, Cohen SM, Pavan PR, Small LB. Family history of Macular Holes. Gass Society Meeting, 2008 Hawaii.

Cohen SM. Natural History of Asymptomatic, Clinical Retinal Detachment. Ophthalmology (Supplement) 2004;225.

Elliot J, Pautler SE, Cohen SM. Pain following retina and vitreous surgery. Ophthalmology (Supplement) 2004;238.

Cukrowski C, Cohen SM. Cystoid Macular Edema Following Pars Plana Vitrectomy for Retained Lens. Ophthalmology (Supplement) 2001;108:262.

Gross JG, Kokame GT, Cohen SM. In-the-bag intraocular lens dislocation. Ophthalmology (Supplement) 2001;108:292.

Cohen SM. Central retinal vein occlusion in diabetics. Vitreous Society Meeting, Cancun, Mexico, 2000.

Cohen SM. Natural History of Asymptomatic Retinal Detachment. Vitreous Society Meeting, Cancun, Mexico, 2000.

Cohen SM, Han DP, Johnson MW, Gass JDM. Foveal retinoschisis in females. Ophthalmology (supplement) 1996;103:185.

Cohen SM, Hammer ME, Grizzard WS. Endophthalmitis after pars plana vitrectomy with or without autologous blood products for macular hole. Ophthalmology (supplement) 1996;103:161.

Ormerod LD, Cohen SM, Davis JL. New Retinal and Choroidal Manifestations of Cat Scratch Disease. Invest Ophthalmol Vis Sci 1995;36:782

Cohen SM, Weishaar PD, Murray TG. Effects of Photocoagulation on Laser Power Transmission Through Human Retina. Invest Ophthalmol Vis Sci 1995;36:833

Hammer ME, Cohen SM, Grizzard WS. Vitrectomy to treat Macular Holes: The Learning Curve. Invest Ophthalmol Vis Sci 1995;36:1050

Lewis ML, Cohen SM, Smiddy WE, Gass JDM. Bilaterality of macular holes. Biannual Meeting of the Club Jules Gonin, Versailles, France, September 9-13, 1994.

Cohen SM, Shen JH, Ren Q, Smiddy WE. Argon, krypton and diode laser transmission through blood. Invest Ophthalmol Vis Sci 1994;35:1750.

Flynn HW, Jr., Cohen SM, Miller D. Endophthalmitis caused by Serratia marcescens. Invest Ophthalmol Vis Sci 1994;35:1993.

Cohen SM, Grajewski AL, Gass JDM, Palmberg PF, Flynn HW, Jr. Treatment of post-trabeculectomy hypotony maculopathy. Ophthalmology (supplement) 1993;100:98.

Callanan D, Davis JL, Cohen SM, Halperin L, Gass JDM. The use of ivermectin in diffuse unilateral subacute neuroretinitis. Ophthalmology (supplement) 1993;100:114.

Gass JDM, Cohen SM. Subretinal fibrosis in multifocal choroiditis. Annual Meeting of the Eastern Ophthalmic Pathology Society, Jekyl Island, Georgia, October 9-11, 1992.

Benner JD, Cohen SM, Landers MB, Morse LS. Intraoperative posterior chamber cultures from vitrectomized patients. Invest Ophthalmol Vis Sci 1992;33:1056.

Cohen SM, Olin KL, Keen CL, Sousa FJ, Morse LS. Antioxidants and trace element analysis in patients with age-related macular degeneration. Ophthalmology (supplement) 1991;98:123.

Cohen SM, Brandt JD, Sousa FJ, Gulyassy P. Ocular hypertensive effect of hemodialysis. Ophthalmology (supplement) 1991;98:109.

Cohen SM, Olin KL, Morse LS, Murphy C, Toth C, Line S, Bellhorn R , Hjelmeland L, Keen CL. Antioxidants and trace element analysis in monkeys and humans with age-related macular degeneration. Invest Ophthalmol Vis Sci 1990;31:356.

Cohen SM, Sullivan C, Albert DM. Effect of sodium butyrate on human Y-79 xenografts in athymic mice. Invest Ophthalmol Vis Sci 1988;29:340.